Mar Dalmau

Mar Dalmau

Auto-generated profile, based on publicly available information

Mar Dalmau

HPB Surgery and Transplants Department Hospital Universitari Vall D'hebron Barcelona Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2024 in Colorectal Disease
Verified
Journal Article
Open access
MDMar Dalmau
Mar Dalmau
MMMarc Martí
Marc Martí
Gianluca PellinoGianluca Pellino
Gianluca Pellino
EBEloy Espin Basany
Eloy Espin Basany
MAManuel Armengol
Manuel Armengol
Aim: We describe two options for colorectal anastomosis suitable in cases when the colon would reach the pelvis under tension. Method: Deloyers procedure and the retro‐ileal colorectal anastomosis are presented, focusing on practical tips and tricks to perform them. Insights on patients who underwent the procedures are provided to demonstrate the advantages and feasibility of the techniques. Results: Each step of both techniques is detailed. Ten patients underwent Deloyers procedure and nine underwent retro‐ileal anastomosis at our unit. A minimally invasive approach was attempted in 13 patients, of whom five required conversion to open surgery due to the technical complexity of the abdominal procedure. Colorectal anastomosis was successfully performed in all patients. There were no major intra‐operative complications, although five patients had postoperative complications requiring further treatment. Conclusions: Both techniques are effective in patients at risk of receiving a colorectal anastomosis under tension, and a minimally invasive approach can be used. However, owing to the complexity of surgery in this group of patients, the perioperative morbidity is not negligible. Careful postoperative management is advisable, and patients should be informed of the risks. In expert hands, the outcomes are acceptable, avoiding an ileorectal anastomosis and its constraints.

12 May 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MDMar Dalmau
Mar Dalmau
RCRamón Charco
Ramón Charco
IBItxarone Bilbao
Itxarone Bilbao
CDCristina Dopazo
Cristina Dopazo
MCMireia Caralt
Mireia Caralt
CGConcepción Gómez-Gavara
Concepción Gómez-Gavara
Background: MicroRNAs have emerged as potential biomarkers of liver injury during organ transplantation due to their specificity, easy detection and stability in many biofluids. Heparin, which has a well-known inhibitory effect on RT-qPCR based measurements, is commonly used during organ donation. Heparinase I treatment has been used to overcome the inhibiting effect of heparin in RNA RT-qPCR analysis. However, there is a lack of evidence regarding its effective, feasible use improving specific miRNA quantification yield in the liver transplant setting. The aim of this study is to evaluate the effect of heparinase I on miRNA detection levels by RT-qPCR in different samples from liver donors. Methods: Prospective, single-centre study including evaluation of liver biopsy, perfusate fluid and serum from deceased organ donors from October 2019 to May 2021. Samples from brain death donors (DBD, n = 4) and donors after circulatory death recovered with abdominal normothermic regional perfusion (DCD n = 4) were analysed for the presence of liver-injury related miRNAs (miR-122 and miR-148a) in the absence or presence of heparinase I (6 IU or 12 IU) to evaluate its effect on miRNA detection levels by RT-qPCR. A subgroup of heparinized serum samples from patients undergoing cardiopulmonary bypass was analysed for validation purposes. The study is registered with ClinicalTrials.gov (NCT06611046), and accrual is complete. Results: The expression of miR-122 relative to reference genes was 44.5, 16.8 and 4.2-fold higher in liver biopsy, perfusates and serum respectively, while miR-148a was 3.4, 2.2 and 2.6-fold higher, without differential expression between donor groups (p > 0.05). Heparinase I treatment did not improve PCR results and affected miRNA detection yields in a dose-dependent way with delayed and dispersed Ct values. In highly heparinized DCD serum samples, heparinase I treatment significantly reduced the relative expression of miR-122 and miR-148a compared to non-treated samples, 2-fold and 6.1-fold, p < 0.05 respectively. Moreover, treatment with heparinase I led to a rise in lost values, from 12.5% to 25% in perfusates and 67.7% to 68.7% in serum samples treated with 6IU and 12IU of heparinase I respectively. Conclusions: The need for heparinase I treatment to overcome RNA quantification interference in heparinized samples should be addressed in each individual analysis. Heparin inhibition seems variable among miRNAs, and the additional handling with heparinase may affect reliable miRNA quantification due to RNA degradation, introducing bias in gene expression interpretation.

23 May 2022 in Colorectal Disease
Verified
Journal Article
Closed access
MMMarc Martí
Marc Martí
MRMar Dalmau Romero
Mar Dalmau Romero
Gianluca PellinoGianluca Pellino
Gianluca Pellino
APAlejandro Solis Peña
Alejandro Solis Peña
EBEloy Espin Basany
Eloy Espin Basany

20 November 2022 in Transplantation Proceedings
Verified
Journal Article
Closed access
MDMar Dalmau
Mar Dalmau
CGConcepción Gómez-Gavara
Concepción Gómez-Gavara
CDCristina Dopazo
Cristina Dopazo
JMJosé Andrés Molino
José Andrés Molino
MCMireia Caralt
Mireia Caralt
EHErnest Hidalgo
Ernest Hidalgo

20 August 2026 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
MMMercadal‐Hally Maria
Mercadal‐Hally Maria
PMPérez Mercedes
Pérez Mercedes
MAMolino José Andrés
Molino José Andrés
BDBarnés Daniel
Barnés Daniel
CMCaralt Mireia
Caralt Mireia
QJQuintero Jesús
Quintero Jesús